Flash FinanceUS
Pre-market S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Krystal Biotech (KRYS)

Krystal Biotech Q3 net income $80.7M on $100M voucher sale; first VYJUVEK sales $8.6M

Positive Impact 3 of 5 earnings Written later

Krystal Biotech reported third quarter 2023 results, with net income of $80.7 million, or $2.88 per basic share, compared with a net loss of $29.9 million a year earlier. The result was driven by a $100 million gain from the sale of a Priority Review Voucher, while the company's loss from operations was $26.0 million and its first VYJUVEK product revenue was $8.6 million. Cash, cash equivalents and investments totaled $598.6 million at September 30, 2023.

Key points

  • Q3 2023 net income was $80.7 million, including a $100 million gain from the sale of a Priority Review Voucher.
  • Q3 2023 product revenues, net were $8.6 million, with 284 VYJUVEK Patient Start Forms received as of the end of the quarter.
  • Nine-month 2023 net income was $2.2 million, compared with a net loss of $107.9 million for the same period in 2022.

The filing

CompanyKrystal Biotech (KRYS)
Form8-K, current report
Filed with the SECNov 6, 2023, 7:10 AM ET
Accession number0001711279-23-000074

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:17 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 06, 2023.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.